Our Development Pipeline
An overview of our programs
Two of our development programs were licensed from established and respected organizations that have already conducted pre-clinical research and, in some cases, clinical research. Our science and regulatory teams are leveraging this research to speed development and commercialization timelines across our growing portfolio.
Dual Agonist Program - Cancer, Cancer-related Anorexia and Weight Loss
ART27.13 is a clinic-ready, potent, peripherally restricted CB1/CB2 synthetic agonist. Existing clinical data with ART27.13 suggests meaningful potential for the treatment of cancer-related anorexia and weight loss (cachexia).
In five Phase I clinical studies including over 200 subjects, ART27.13 demonstrated a statistically significant and dose-proportional increase in body weight. In ongoing consultation with regulatory authorities, we plan to advance ART27.13 as a multi-modal supportive care therapy for cancer patients suffering from anorexia or weight loss.
Numerous non-peripherally restricted CB1 and CB2 agonists have shown promising results as anti-tumor drugs, yet their profile made them unsuitable for further development. In cooperation with the NEOMED Institute (Montreal, Canada), we are evaluating ART27.13, our peripherally restricted agonist, for its anti-cancer potential.
CBD Composition Program - Stroke, IBD, Rare Diseases
Our team and scientific collaborators discovered a novel composition of cannabidiol (CBD) that has demonstrated superior pharmaceutical properties compared to existing formulations. We are pursuing development of ART12.11 for multiple indications, including stroke and inflammatory bowel diseases (e.g., Colitis and Crohn’s), as well as rare diseases.
FABP5 Inhibitor Program - Cancer, Inflammation and Pain
Through an exclusive agreement and in collaboration with The Research Foundation of the State University of New York Stony Brook, we are developing a Fatty Acid Binding Protein 5 (FABP5) inhibitor to modulate the endocannabinoid system for the treatment of cancer, inflammation, and pain.
Fatty Acid Binding Proteins have been identified as intracellular transporters for the endocannabinoid anandamide (AEA), a neurotransmitter produced in the brain that binds to CB1 and CB2 receptors. Inhibition of FABP5 will lead to higher levels of AEA and may have significant potential in treating pain. Animal studies have demonstrated that elevated levels of endocannabinoids can result in beneficial pharmacological effects on stress, pain, and inflammation, and may ease the effects of drug withdrawal.
Additionally, FABP5 and PPARß/δ are critical mediators of epidermal growth factor receptor-induced carcinoma cell growth. We are working with Stony Brook University to optimize a FABP5 inhibitor for the treatment of breast and prostate cancers.